Bone mineral disorder in chronic kidney disease: Klotho and FGF23; cardiovascular implications.

Laura Salanova Villanueva, Carmen Sánchez González, José Antonio Sánchez Tomero, Abelardo Aguilera, Esther Ortega Junco
Author Information
  1. Laura Salanova Villanueva: Servicio de Nefrología, Hospital de La Princesa, Madrid, España. Electronic address: aelita.sv@gmail.com.
  2. Carmen Sánchez González: Servicio de Nefrología, Hospital de La Princesa, Madrid, España.
  3. José Antonio Sánchez Tomero: Servicio de Nefrología, Hospital de La Princesa, Madrid, España.
  4. Abelardo Aguilera: Servicio de Nefrología, Hospital de La Princesa, Madrid, España.
  5. Esther Ortega Junco: Servicio de Nefrología, Hospital de La Princesa, Madrid, España.

Abstract

Cardiovascular factors are one of the main causes of morbidity and mortality in patients with chronic kidney disease. Bone mineral metabolism disorders and inflammation are pathological conditions that involve increased cardiovascular risk in chronic kidney disease. The cardiovascular risk involvement of bone mineral metabolism classical biochemical parameters such as phosphorus, calcium, vitamin D and PTH is well known. The newest markers, FGF23 and klotho, could also be implicated in cardiovascular disease.

Keywords

MeSH Term

Animals
Biomarkers
Bone and Bones
Calcineurin
Cardiovascular Diseases
Chronic Kidney Disease-Mineral and Bone Disorder
Fibroblast Growth Factor-23
Fibroblast Growth Factors
Glucuronidase
Humans
Klotho Proteins
Mice
Minerals
Models, Biological
Parathyroid Hormone
Phosphorus
Renal Insufficiency, Chronic
Risk Factors
Vascular Calcification
Vitamin D

Chemicals

Biomarkers
FGF23 protein, human
Fgf23 protein, mouse
Minerals
Parathyroid Hormone
Vitamin D
Phosphorus
Fibroblast Growth Factors
Fibroblast Growth Factor-23
Calcineurin
Glucuronidase
Klotho Proteins